Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) in a research note issued to investors on Tuesday. The firm set a "hold" rating on the biopharmaceutical company's stock.

Separately, HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, January 21st.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock traded up $0.01 during mid-day trading on Tuesday, reaching $4.46. 297,192 shares of the company traded hands, compared to its average volume of 592,512. Vanda Pharmaceuticals has a 52-week low of $3.46 and a 52-week high of $6.75. The firm has a market capitalization of $259.77 million, a price-to-earnings ratio of -15.91 and a beta of 0.77. The firm's 50 day moving average price is $4.74 and its 200 day moving average price is $5.00.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company's stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.90% of the company's stock.

Institutional Trading of Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its holdings in Vanda Pharmaceuticals by 17.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company's stock worth $11,379,000 after acquiring an additional 292,172 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth about $75,000. AQR Capital Management LLC boosted its stake in Vanda Pharmaceuticals by 181.7% in the 2nd quarter. AQR Capital Management LLC now owns 75,889 shares of the biopharmaceutical company's stock worth $429,000 after purchasing an additional 48,945 shares in the last quarter. Susquehanna Fundamental Investments LLC increased its stake in Vanda Pharmaceuticals by 2.1% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company's stock valued at $1,625,000 after purchasing an additional 5,994 shares in the last quarter. Finally, Nantahala Capital Management LLC raised its holdings in Vanda Pharmaceuticals by 57.3% in the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company's stock worth $9,003,000 after buying an additional 580,265 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.